- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05556044
Empagliflozin for New On-set Heart Failure Study Regardless of Ejection Fraction (EMPA)
In-hospital Initiation of Empagliflozin for the Treatment of New-onset Acute Heart Failure Regardless of Ejection Fraction: A Pilot Study
Heart failure (HF) is one of the most important reasons for hospital admission and is associated with high mortality and morbidity. After discharge, up to 40% of patients are readmitted within 6 months and 1-year post-discharge mortality is high. The cost burden of treating patients with HF is high and ~80% of healthcare costs are related to hospital admissions.
Sodium-glucose cotransporter-2 (SGLT2) inhibitor is considered one of the four foundational therapies (ACE-I or ARNI, beta-blockers, MRA, and SGLT2 inhibitors) for HFrEF. In particular, empagliflozin has been shown in randomized controlled trials to reduce the combined risk of cardiovascular death or HF hospitalization in HF patients with both reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF). However, guidelines do not specify the sequence and the timing of which therapy to be commenced. The timing of SGLT inhibitors initiation in the treatment of acute HF is not established. In particular, new-onset acute HF is a group which is understudied in the major trials to date. This study aims to evaluate the efficacy and safety of in-hospital initiation of empagliflozin in patients hospitalized for new onset acute HF, regardless of LVEF for up to 90 days of follow-up.
Study Overview
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Daniel Xu
- Phone Number: 1518 35051518
- Email: danielxu@cuhk.edu.hk
Study Locations
-
-
-
Shatin, Hong Kong, 999077
- Recruiting
- The Chinese University of Hong Kong
-
Contact:
- Daniel Xu
- Phone Number: 1518 35051518
- Email: danielxu@cuhk.edu.hk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subject age >18 hospitalized for primary diagnosis of acute HF
- Dyspnoea (exertional or at rest) and 2 of the following signs: Congestion on chest X-ray; Rales on chest auscultation; Clinically relevant oedema (e.g. ≥1+ on a 0 to 3+ scale); Elevated jugular venous pressure
- Stabilization criteria (while in the hospital): systolic blood pressure ≥100mmHg and no symptoms of hypotension in the preceding 24 hours; No increase in i.v. diuretic dose for 24 h prior; No i.v. vasodilators including nitrates within the last 24 h prior; No i.v. inotropic drugs for 24 h prior
NT-proBNP ≥1600 pg/mL or BNP ≥400 pg/mL. (Patients with atrial fibrillation: NT-proBNP ≥2400 pg/mL or BNP
≥600 pg/mL. Measured during index hospitalization
- Heart failure hospitalization that requires the treatment of a minimum single dose of 40 mg of i.v.
furosemide( or Equivalent i.v loop diuretics defined as 20 mg of torsemide or 1mg of bumetanide)
Exclusion Criteria:
- Cardiogenic shock
- Documented history of HF with previous HF admission
- Current hospitalization for acute HF primarily triggered by pulmonary embolism, cerebrovascular accident, or acute myocardial infraction
- Interventions in the past 30 days prior or planned during the study: Major cardiac surgery, or Transcatheter aortic valve implantation (TAVI), or percutaneous coronary intervention (PCI), or MitraClip; Implantation of cardiac resynchronization therapy device; Cardiac mechanical support implantation
- Current or expected heart transplant, left ventricular assist device (LVAD), intraaortic balloon pumping (IABP), or patients with planned inotropic support in an outpatient setting
- Haemodynamically severe uncorrected primary cardiac valvular disease planned for surgery or intervention during the course of the study
- eGFR <20 mL/min/1.73m2 as measured during index hospitalization (latest measurement before randomization) or patients requiring dialysis
- Type 1 diabetes mellitus (DM)
- History of ketoacidosis, including diabetic ketoacidosis
- Current or prior treatment with SGLT2 inhibitors in the 90 days prior to enrolment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Empagliflozin 10 MG
|
This is an investigator-initiated, prospective, single-centre, non-randomized open label study that evaluates the efficacy and safety of initiating empagliflozin during index hospitalization for acute heart failure regardless of LVEF.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Heart failure (HF) events
Time Frame: 90 days
|
Number of heart failure events (including hospitalization for HFs, urgent heart failure visits and unplanned outpatient visits), time to first heart failure event.
|
90 days
|
All-cause mortality
Time Frame: 90 days
|
All-cause mortality after 90 days of treatment
|
90 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Kansas City Cardiomyopathy Questionnaire - Total Symptom Score (KCCQ-TSS)
Time Frame: 90 days
|
Change from baseline in KCCQ-TSS.
Scores are transformed to a range of 0-100, where higher scores reflect better health status.
|
90 days
|
NT-proBNP level
Time Frame: 90 days
|
Change from baseline in log-transformed NT-proBNP level
|
90 days
|
New York Heart Association (NYHA) class
Time Frame: 90 days
|
Change in NYHA class (I-IV), Class IV is most severe; Class I least severe
|
90 days
|
Major Adverse Cardiovascular Event (MACE)
Time Frame: 90 days
|
Measure the occurrence of MACE, including Days alive and out of hospital, occurrence of hypertensive Heart failure from study drug initiation until 90 days after initial hospital discharge and randomization; Time to first occurrence of cardiovascular death or heart failure event until end of trial visit
|
90 days
|
Occurrence of kidney damage
Time Frame: 90 days
|
Occurrence of chronic dialysis or renal transplant or sustained reduction of ≥40% estimated glomerular filtration rate (eGFR), or
|
90 days
|
Weight loss
Time Frame: 90 days
|
Weight loss per mean daily loop diuretic dose after 15, 30, 60 and 90 days of treatment.
|
90 days
|
Quality-adjusted life years (QALY) gained
Time Frame: 90 days
|
Quality-adjusted life years (QALY) gained due to early initiation of empagliflozin
|
90 days
|
Change in 6 minute hall walk (6MHW)
Time Frame: 90 days
|
Change from baseline in 6MHW result
|
90 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Bryan Yan, Chinese University of Hong Kong
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021.717-T
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Heart Failure
-
Idorsia Pharmaceuticals Ltd.CompletedAcute Heart Failure | Acute Decompensation of Chronic Heart Failure | New Onset of Heart FailureUnited States, United Kingdom, Israel, Switzerland, Austria, Denmark, France, Germany, Greece, Poland
-
Idorsia Pharmaceuticals Ltd.CompletedAcute Heart Failure | Acute Decompensation of Chronic Heart Failure | New Onset of Heart FailureUnited States, Hungary, Australia, Czechia, Germany, Italy, Norway, United Kingdom
-
Abiomed Inc.RecruitingHeart Diseases | Acute Decompensated Heart Failure | Congestive Heart Failure | Acute Heart FailureUnited States
-
Shanghai Chest HospitalUnknownAcute Renal Failure | Acute Heart FailureChina
-
Magenta Medical Ltd.TerminatedCongestive Heart Failure | Heart Failure, Congestive | Acute Heart FailureCroatia, Belgium, Serbia
-
University Medical Center GroningenCompletedHeart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteNetherlands
-
Jordan Cardio Vascular Research GroupRecruitingHeart Failure | Chronic Heart Failure | Acute Heart FailureJordan
-
University Hospital, Clermont-FerrandHospices Civils de Lyon; University Hospital, Grenoble; Hôpital de la Croix-Rousse and other collaboratorsRecruitingHeart Failure | Chronic Heart Failure | Acute Heart FailureFrance
-
Azienda Ospedaliera Città della Salute e della...Caretek S.r.l. Turin, Italy; Santer Reply S.p.A. Milan, ItalyUnknownHeart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteItaly
-
Indiana UniversityWayne State University; Vanderbilt University; Case Western Reserve University; Inova Fairfax HospitalCompletedHeart Failure | Acute Cardiac Failure | Acute Cardiac Pulmonary Edema | Heart Failure AcuteUnited States
Clinical Trials on Empagliflozin 10 MG
-
Instituto Nacional de Cardiologia Ignacio ChavezNot yet recruitingSTEMI | No-Reflow Phenomenon
-
Damanhour UniversityRecruitingHeart Failure | Reduced Ejection Fraction Heart FailureEgypt
-
Boehringer IngelheimEli Lilly and CompanyCompletedDiabetes Mellitus, Type 2Japan
-
Boehringer IngelheimEli Lilly and CompanyCompleted
-
Collegium Medicum w BydgoszczyRecruitingMetabolic SyndromePoland
-
Boehringer IngelheimCompleted
-
Yale UniversityBoehringer IngelheimRecruitingEnd Stage Renal Disease on DialysisUnited States
-
University of Mississippi Medical CenterEli Lilly and CompanyRecruiting
-
Butler HospitalNational Institute of Mental Health (NIMH)CompletedSubstance-Related Disorders | Depression | HIV InfectionsUnited States
-
The University of Hong KongResearch Grant CouncilRecruitingCirrhosis | NAFLD | Chronic Hepatitis b | Fibrosis, Liver | Empagliflozin | SGLT2 InhibitorsHong Kong